ClinicalTrials.gg
CompletedNCT01744691Updated Feb 27, 2017Results posted

A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion

A Phase 2 interventional study of Ibrutinib in Chronic Lymphocytic Leukemia With 17p Deletion and Small Lymphocytic Lymphoma With 17p Deletion, sponsored by Pharmacyclics LLC.. Completed at 55 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-02-27.

Sponsored by Pharmacyclics LLC. (part of AbbVie) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
145
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 8 open to participants now, 28 under way, 4 of them phase 3. ibrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
19th of 83
145 · median 44
Started
2013
with 6 others
Phase 2
43 of 83
6 open now
Registered
13th of 83
by date
Lead sponsor
10 of 83
Pharmacyclics LLC.

Among the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 19th largest by enrollment, is one of 7 that started in 2013, is one of 43 in phase 2, and was the 13th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

8 of the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About ibrutinib

ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 188 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

An Open-label, Single arm, Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma with 17p Deletion

Read the detailed description

This is a multicenter, international, open-label, single arm, Phase 2 study designed to evaluate the efficacy and safety of ibrutinib in subjects with relapsed/refractory CLL or SLL with del 17p. All subjects will receive ibrutinib until disease progression or unacceptable toxicity occurs.

03

Conditions studied

  • Chronic Lymphocytic Leukemia With 17p Deletion
  • Small Lymphocytic Lymphoma With 17p Deletion

Keywords

  • CLL
  • SLL
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Documentation of del (17p13.1)
  • Must have CLL/SLL after receiving at least 1 .
  • Measurable nodal disease by computed tomography (CT)

Key Exclusion Criteria:

  • History or current evidence of Richter's transformation or prolymphocytic leukemia
  • Prior hematologic stem cell transplantation \<6 months from study enrollment or any ongoing
  • Prior exposure to ibrutinib
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
145 participants (actual)

Study arms

  • Experimental
    ibrutinib

    All subjects will receive ibrutnib 420 mg (3 x 140-mg capsules) orally once daily.

    Drug: Ibrutinib

Interventions

  • All subjects will receive ibrutinib 420 mg (3 x 140-mg capsules) orally once daily.

06

What researchers measure

Primary outcomes

  1. Overall Response Rate

    The primary objective of this study is to evaluate the efficacy of ibrutinib in terms of ORR according to an Independent Review Committee (IRC). ORR based upon IRC assessment is the proportion of responders in the all treated population. Responders were subjects who achieved partial response (PR) or better, ie, complete response (CR), complete response with incomplete marrow recovery (CRi), nodule partial response (nPR) or PR, per IWCLL 2008 criteria with the clarification for treatment-related lymphocytosis.

    Time frame: The median time on study for all treated participants is 33.3 (range 0.5 - 40.1) months

Secondary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (AEs)

    Number of participants who had experienced at least one treatment emergent AE

    Time frame: From first dose of PCI-32765 to within 30 days of last dose for each participant or until study closure

07

Results

Posted Jun 9, 2015

Participant flow

Participant flow — Overall Study
MilestoneIbrutinib
Started144
Completed101
Not completed43
Withdrew: Progressive disease18
Withdrew: Unacceptable toxicity, ae or death18
Withdrew: Withdrawal of consent for treatment3
Withdrew: Physician decision4

Outcome measures

PrimaryOverall Response Rate

The primary objective of this study is to evaluate the efficacy of ibrutinib in terms of ORR according to an Independent Review Committee (IRC). ORR based upon IRC assessment is the proportion of responders in the all treated population. Responders were subjects who achieved partial response (PR) or better, ie, complete response (CR), complete response with incomplete marrow recovery (CRi), nodule partial response (nPR) or PR, per IWCLL 2008 criteria with the clarification for treatment-related lymphocytosis.

Time frame:
The median time on study for all treated participants is 33.3 (range 0.5 - 40.1) months
Reported as:
Number · % of participants with response by PI
Overall Response Rate
% of participants with response by PIIbrutinib
Overall Response Rate77.8 (70.3 to 83.8)
SecondaryNumber of Participants With Treatment Emergent Adverse Events (AEs)

Number of participants who had experienced at least one treatment emergent AE

Time frame:
From first dose of PCI-32765 to within 30 days of last dose for each participant or until study closure
Reported as:
Number · participants
Number of Participants With Treatment Emergent Adverse Events (AEs)
participantsPCI-32765
Number of Participants With Treatment Emergent Adverse Events (AEs)144

Adverse events

Collected over From first dose of PCI-32765 to within 30 days of last dose. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PCI-32765—76/144 (52.8%)144/144 (100%)
Most frequent serious events
Showing 10 of 118
Most frequent serious events
EventPCI-32765
PneumoniaInfections and infestations21/144
Atrial fibrillationCardiac disorders8/144
Richter's syndromeNeoplasms benign, malignant and unspecified (incl cysts and polyps)6/144
Urinary tract infectionInfections and infestations5/144
Chronic lymphocytic leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)5/144
AnaemiaBlood and lymphatic system disorders4/144
CellulitisInfections and infestations4/144
PyrexiaGeneral disorders3/144
Subdural haematomaInjury, poisoning and procedural complications3/144
Pleural effusionRespiratory, thoracic and mediastinal disorders3/144
Most frequent other events
Showing 10 of 70
Most frequent other events
EventPCI-32765
DiarrhoeaGastrointestinal disorders63/144
FatigueGeneral disorders54/144
CoughRespiratory, thoracic and mediastinal disorders46/144
ArthralgiaMusculoskeletal and connective tissue disorders41/144
HypertensionVascular disorders39/144
NauseaGastrointestinal disorders34/144
AnaemiaBlood and lymphatic system disorders33/144
PyrexiaGeneral disorders31/144
Upper respiratory tract infectionInfections and infestations30/144
Urinary tract infectionInfections and infestations30/144

Baseline characteristics

One hundred forty-five subjects were enrolled and 144 subjects received at least 1 dose of PCI-32765 and constitute the all treated population and the safety analysis set.

Age, Categorical
Age, Categorical(Participants)PCI-32765
<=18 years0
Between 18 and 65 years75
>=65 years69
Age, Continuous
Age, Continuous(years)PCI-32765
Mean64.4 ± 9.9
Gender
Gender(Participants)PCI-32765
Female48
Male96
08

Study locations

55 sites
  • Phoenix, Arizona, United States
  • Duarte, California, United States
  • Greenbrae, California, United States
  • La Jolla, California, United States
  • Stanford, California, United States
  • Tampa, Florida, United States
  • Chicago, Illinois, United States
  • Boston, Massachusetts, United States
  • Ann Arbor, Michigan, United States
  • Rochester, Minnesota 55905, United States
  • St. Louis, Missouri, United States
  • Hackensack, New Jersey, United States
  • New Hyde Park, New York, United States
  • New York, New York, United States
  • Goldsboro, North Carolina, United States
  • Columbus, Ohio, United States
  • Toldedo, Ohio, United States
  • Houston, Texas, United States
  • Adelaide, Australia
  • Coburg, Australia
  • East Melbourne, Australia
  • Fremantle, Australia
  • Antwerp, Belgium
  • Brugge, Belgium
  • Brussels, Belgium
  • Gent, Belgium
  • Kortrijk, Belgium
  • Leuven, Belgium
  • Roeselare, Belgium
  • Edmonton, Alberta, Canada
  • Cologne, Germany
  • Dresden, Germany
  • Heidelberg, Germany
  • Munich, Germany
  • Ulm, Germany
  • Auckland, New Zealand
  • Christchurch, New Zealand
  • Goteborg, Sweden
  • Lund, Sweden
  • Stockholm, Sweden
  • Ankara, Turkey
  • Gaziantep, Turkey
  • Istanbul, Turkey
  • Izmir, Turkey
  • Kayseri, Turkey
  • Bournemouth, United Kingdom
  • Glasgow, United Kingdom
  • Leeds, United Kingdom
  • Leicester, United Kingdom
  • Liverpool, United Kingdom
  • London, United Kingdom
  • Manchester, United Kingdom
  • Newcastle upon Tyne, United Kingdom
  • Oxford, United Kingdom
  • Plymouth, United Kingdom
09

References and documents

Publications

  • O'Brien S, Jones JA, Coutre SE, Mato AR, Hillmen P, Tam C, Osterborg A, Siddiqi T, Thirman MJ, Furman RR, Ilhan O, Keating MJ, Call TG, Brown JR, Stevens-Brogan M, Li Y, Clow F, James DF, Chu AD, Hallek M, Stilgenbauer S. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016 Oct;17(10):1409-1418. doi: 10.1016/S1470-2045(16)30212-1. Epub 2016 Sep 13. PubMed 27637985 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2013, a primary completion of Jun 2014 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2015, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2012
First posted
Dec 7, 2012
Start
Jan 2013
Primary completionActual
Jun 2014
CompletionActual
Apr 2016
Results first posted
Jun 9, 2015
Last update
Feb 27, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01744691
Lead sponsor
Pharmacyclics LLC.
Responsible party
Sponsor
First posted
Dec 7, 2012
Start date
Jan 2013
Primary completion
Jun 2014
Completion
Apr 2016
Results posted
Jun 9, 2015
Last update
Feb 27, 2017

Study contacts

Alvina Chu, MD
study director · Pharmacyclics LLC.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibrutinib

Start the discussion